Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.
What Is the Forecast for the Progressive Multifocal Leukoencephalopathy Treatment Market Growth in 2025?
In recent times, the market size of the treatment for progressive multifocal leukoencephalopathy has seen substantial expansion. Projected figures indicate a surge from $1.46 billion in 2024, to an increased $1.61 billion in 2025, signifying a compound annual growth rate (CAGR) of 10.6%. This notable market expansion throughout the historical phase could be linked to several factors including the growing number of patients with underlying conditions, an increase in immunosuppressed patients, amplified patient advocacy and awareness efforts, and the escalation of the HIV/AIDs epidemic.
What Is the Forecast for the Progressive Multifocal Leukoencephalopathy Treatment Market Size Through 2029?
In the upcoming years, the market size for treatment of progressive multifocal leukoencephalopathy is anticipated to experience a swift expansion, reaching $2.38 billion by 2029 with a Compound Annual Growth Rate (CAGR) of 10.2%. This enlargement in the projected timeline can be credited to the rise in digital health and telemedicine, increasing endorsement of targeted therapy, advancement in diagnostic tools, and heightened awareness around progressive multifocal leukoencephalopathy (PML). The prediction period will be characterized by significant trends such as technological progression in PML treatment, research and clinical testing, premature diagnosis and screening alongside the progression of innovative drug therapies.
Download The Free Sample Report Here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=12864&type=smp
What are the Key Market Players in Progressive Multifocal Leukoencephalopathy Treatment Market and How They’re Evolving?
Major companies operating in the progressive multifocal leukoencephalopathy treatment market are Pfizer Inc., Johnson & Johnson, Roche Holding AG, Merck & Co. Inc., AbbVie Inc., Novartis AG, Bristol Myers Squibb Company, Sanofi S.A., Takeda Pharmaceutical Company Limited, Acorda Therapeutics, Eli Lilly and Company, Gilead Sciences Inc., Amgen Inc., Viatris Inc., Teva Pharmaceutical Industries Ltd., Biogen Inc., Eisai Co. Ltd., Otsuka Pharmaceutical Co. Ltd., Jazz Pharmaceuticals PLC, Ipsen Pharma, Apotex Inc., Alkermes PLC, Alnylam Pharmaceuticals Inc., Genentech Inc., Karyopharm Therapeutics Inc., ARIAD Pharmaceuticals Inc., Spectrum Pharmaceuticals, Neurimmune AG, NeoImmuneTech, Inhibikase Therapeutics Inc.
What Are the Primary Growth Drivers in the Progressive Multifocal Leukoencephalopathy Treatment Market?
The increasing incidence of Human Immunodeficiency Virus (HIV) infection is anticipated to accelerate the expansion of the progressive multifocal leukoencephalopathy market. HIV, a type of retrovirus, launches an attack on the immune system, predominantly impacting CD4 cells (also referred to as T cells) that are fundamental in enabling the body to combat infections. The majority of those affected by HIV are likely to develop PML due to the inadequacy of their immune system, illustrated by a diminished CD4 cell count (200/L), the primary cause of PML instances globally. When a significant immune deficit associated with HIV emerges, there might be an increase in the dormant JCV archetype strain in the brain. This could result in lesions on the brain’s white matter and PML. According to data from the Joint United Nations Programme on HIV and AIDS (UNAIDS), a Switzerland-based collaboration of the United Nations for AIDS, in December 2022, 630,000 (480,000–880,000) people succumbed to AIDS-related illnesses. There were also 39.0 million [33.1 million–45.7 million] individuals globally living with HIV. Moreover, in 2022, 1.3 million [1 million–1.7 million] people newly developed HIV. Consequently, the escalating rate of HIV infection is fueling the growth of the progressive multifocal leukoencephalopathy market. The surge in research and development activities is predicted to fuel the expansion of the progressive multifocal leukoencephalopathy treatment market. This surge pertains to the amplified endeavors and investments being allocated towards science-based inquiry, trials, and innovation in various areas. These activities are crucial for the successful treatment and control of progressive multifocal leukoencephalopathy (PML), as they contribute to the development of improved therapies, more timely diagnosis, and better disease management. For example, as per Eurostat, a government agency based in Luxembourg, in 2022 the EU assigned €352 billion ($380.40 billion) to research and development (R&D), marking a 6.34% escalation from the €331 billion ($357.71 billion) invested in 2021. Hence, the increasing emphasis on research and development activities is propelling the growth of the progressive multifocal leukoencephalopathy treatment market.
Request For A Customized Report:
https://www.thebusinessresearchcompany.com/customise?id=12864&type=smp
What Are the Leading Segments in the Global Progressive Multifocal Leukoencephalopathy Treatment Industry?
The progressive multifocal leukoencephalopathy treatment market covered in this report is segmented –
1) By Treatment: Anti-retroviral Therapy, Antiviral Or Anti-John Cunningham Virus (JCV), Other Symptomatic
2) By Indication: HIV Or AIDS, Organ Transplantation, Multiple Sclerosis, Hematologic Malignancies
3) By Route of Administration: Oral, Parenteral, Other Routes Of Administration
4) By End-Users: Hospitals, Homecare, Specialty Centers, Other End-Users
Subsegments:
1) By Anti-retroviral Therapy: NRTIs (Nucleoside Reverse Transcriptase Inhibitors), NNRTIs (Non-Nucleoside Reverse Transcriptase Inhibitors), PIs (Protease Inhibitors), Integrase Inhibitors
2) By Antiviral Or Anti-John Cunningham Virus (JCV): Natalizumab, Fumaric Acid Esters, Other JCV-targeted Therapies
3) By Other Symptomatic Treatments: Corticosteroids, Immunomodulators, Supportive Care, Symptomatic Relief Medications
What Are the Key Market Trends in the Progressive Multifocal Leukoencephalopathy Treatment Industry?
Leading firms in the advanced multifocal leukoencephalopathy treatment market are concentrating on product development to offer dependable solutions to their clientele and solidify their market standing. In particular, October 2022 saw the clearance for an investigational new drug (IND) application and orphan drug designation for CE-VST01-JC by Cellevolve Bio, a U.S.-based clinical enterprise, endorsed by the Food and Drug Administration. This medication is designed to tackle progressive multifocal leukoencephalopathy and is set to undergo evaluation in a global, multi-center, randomized, double-blind, placebo-controlled second-phase trial named ASCEND-JC. The objective of this endeavor is to juxtapose CE-VST01-JC with a placebo to scrutinize if CE-VST01-JC can mitigate or prevent neurological advancement in PML patients. CE-VST01-JC, a T-cell therapy focusing on the JC virus, the PML’s originator, is a momentous development for both PML community and Cellevolve, as the largest cellular treatment research in PML history will be ASCEND-JC.
Access The Full Report Here:
What Is the Regional Outlook for the Progressive Multifocal Leukoencephalopathy Treatment Market?
North America was the largest region in the progressive multifocal leukoencephalopathy treatment market in 2024. The regions covered in the progressive multifocal leukoencephalopathy treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
Purchase The Full Report Today:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=12864
This Report Delivers Insight On:
1. How big is the progressive multifocal leukoencephalopathy treatment market, and how is it changing globally?
2. Who are the major companies in the progressive multifocal leukoencephalopathy treatment market, and how are they performing?
3. What are the key opportunities and risks in the progressive multifocal leukoencephalopathy treatment market right now?
4. Which products or customer segments are growing the most in the progressive multifocal leukoencephalopathy treatment market?
5. What factors are helping or slowing down the growth of the progressive multifocal leukoencephalopathy treatment market?
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 2071930708
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
